C-EUBCmicellar resveratrol, neuroinflammation, oral softgel
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Evaluate JOTROL as a treatment candidate for patients with Parkinson's disease.
Exploratory Phase 2a clinical trial designed to evaluate safety and tolerability, with secondary and exploratory endpoints assessing pharmacokinetics and related measures.
FDA cleared the IND application to initiate a Phase 2a clinical trial of JOTROL in Parkinson's disease.
Develop a patented micellar oral softgel formulation of resveratrol with improved bioavailability for neuroinflammation-related CNS and rare disease indications.
Micellar 10% resveratrol solubilization formulation delivered orally as a softgel; first-in-human ascending single-dose safety and pharmacokinetic evaluation up to 700 mg resveratrol as JOTROL.
Company highlighted JOTROL's bioavailability and CNS-targeted science in July 2025; prior first-in-human study reported dose-related exposure and urinary recovery consistent with high absorption.
After a single 500 mg JOTROL dose, reported Cmax was 455 ng/mL; exposures increased with dose and appeared higher than dose-proportional for AUC0-t and Cmax. Less than 1% of drug-related material was intact relative to key metabolites in plasma and urine.
Develop JOTROL as a potential prophylaxis and/or treatment for Alzheimer's disease or mild cognitive impairment through neuroprotective and anti-inflammatory effects.
Oral JOTROL evaluated in 3xTg-AD mouse studies, including 36-day sub-chronic reversal treatment in 15-month-old male mice and 9-month prophylactic treatment starting at 4 months of age; behavioral, mRNA, protein, cytokine, and AD-related biomarker analyses were performed.
Preclinical mouse study published in 2022; human studies in Alzheimer's patients were described as in development in the first-in-human pharmacokinetic publication.
JOTROL showed increased bioavailability over non-formulated resveratrol and produced AD-related gene expression changes, including Adam10, Bace1, Bdnf, and Psen1, plus changes in inflammatory genes and cytokine levels.
Pursue use of JOTROL/resveratrol in Friedreich's ataxia, a rare disease indication.
Oral micellar resveratrol formulation.
First-in-human JOTROL publication stated Jupiter was pursuing use of resveratrol in Friedreich's ataxia.
Pursue use of JOTROL/resveratrol in mucopolysaccharidosis type 1, a rare orphan disease indication.
Oral micellar resveratrol formulation; studies in MPS 1 patients were described as in development.
First-in-human JOTROL publication stated that studies in MPS 1 were in development.